SAMN38102777
External Id
Merck & Co., Inc.
INSDC center name
2023-11-04T00:00:00Z
INSDC first public
2023-11-04T19:01:42.247Z
INSDC last update
SRS19417002
INSDC secondary accession
live
INSDC status
SARS-CoV-2: clinical or host-associated
NCBI submission model
SARS-CoV-2.cl.1.0
NCBI submission package
SRS19417002
SRA accession
Control
antiviral_treatment_agent
Aaron Diamond AIDS Research Center, Columbia University Medical Center
collected_by
2022
collection_date
Viral RNA from culture supernatants was collected for each replicate culture, at each passage, and purified using the PureLink Pro 96 Viral RNA/DNA Purification Kit (ThermoFisher, Massachusetts, USA). Whole genome SARS-CoV-2 sequencing libraries were prepared via the QIAseq DIRECT SARS-CoV-2 kit (Qiagen, Hilden, Germany). Sequencing was performed on the Illumina platform, yielding 2 × 151 nucleotide paired-end reads.
description
USA: New York
geo_loc_name
Homo sapiens
host
COVID-19
host_disease
Vero E6 cells
isolate
BSL-3 Laboratory
isolation_source
Severe acute respiratory syndrome coronavirus 2
http://purl.obolibrary.org/obo/NCBITaxon_2697049
organism
culture supernatant (100 µL) from wells with the highest drug concentration exhibiting >10% cytopathic effect were used to seed the next passage
passage_method
4
passage_number
A
replicate
DNA Sequencing and Genotyping Center, University of Delaware, Newark, Delaware, USA
sequenced_by
SARS-CoV-2: clinical or host-associated sample from Severe acute respiratory syndrome coronavirus 2
title